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Background: Parkinson’s disease (PD) is a chronic neurodegenerative condition that is characterized by motor
symptoms as a result of dopaminergic degeneration, particularly in the mesostriatal pathway. However, in recent
years, a greater number of clinical studies have focused on the emergence of non-motor symptoms in PD patients,
as a consequence of damage on the mesolimbic and mesocortical dopaminergic networks, and on their significant
impact on the quality of life of PD patients. Herein, we performed a thorough behavioral analysis including motor,
emotional and cognitive dimensions, of the unilateral medial forebrain bundle (MFB) 6-hydroxidopamine (6-OHDA)-
lesioned model of PD, and further addressed the impact of pharmacological interventions with levodopa and
antidepressants on mood dimensions.
Results: Based on apomorphine-induced turning behaviour and degree of dopaminergic degeneration, animals
submitted to MFB lesions were subdivided in complete and incomplete lesion groups. Importantly, this division also
translated into a different severity of motor and exploratory impairments and depressive-like symptoms; in contrast,
no deficits in anxiety-like and cognitive behaviors were found in MFB-lesioned animals. Subsequently, we found
that the exploratory and the anhedonic behavioural alterations of MFB-lesioned rats can be partially improved with
the administration of both levodopa or the antidepressant bupropion, but not paroxetine.
Conclusions: Our results suggest that this model is a relevant tool to study the pathophysiology of motor and
non-motor symptoms of PD. In addition, the present data shows that pharmacological interventions modulating
dopaminergic transmission are also relevant to revert the non-motor behavioral deficits found in the disease.
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Parkinson’s disease (PD) is a complex neurodegenerative
chronic disease affecting the dopaminergic system. First
described by James Parkinson in 1817 [1], this disease
affects mainly the substantia nigra pars compacta (SNc),
also designated as area A9, where a massive dopaminergic
degeneration takes place [2-4]. This brain area is the
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reproduction in any medium, provided the orcaudate/putamen complex [5]. Thus, degeneration in this
pathway causes functional disruption of basal ganglia’s cir-
cuitry [6], and the emergence of several physical hallmarks
of PD, such as bradykinesia and tremors [7]. Though to a
lesser extent, the mesocorticolimbic dopaminergic path-
way, originated in area A10, is also affected as the disease
progresses [8-11]. This event will lead to the development
of several non-motor features of PD including depression,
apathy, anhedonia, and dementia [8,12-14]. Although it
was somewhat disregarded in the past, more recent
evidence has shown that mood and cognitive changesal Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of the patients [15,16].
The development of animal models of PD, using both
genetic and toxin-based approaches, was of great im-
portance to the field, as it improved our knowledge on
the pathophysiological mechanisms of the disease and
provided experimental tools for testing novel therapies.
Among PD models, the unilaterally 6-hydroxidopamine
(6-OHDA)-lesioned rat is one of particular interest
[17,18]. The lesion protocol, usually done in the medial
forebrain bundle (MFB), is known to cause significant
motor deficits; and given its unilateral nature, it causes an
inter-hemispheric imbalance in dopamine (DA) transmis-
sion that permits the assessment of a quantifiable turning
behavior, which can be correlated with the extension of
the lesion [19-23]. However, since PD is known to have
significant impact in mood and cognition, it is of the ut-
most importance to identify and characterize additional
behavioral features besides motor disabilities, in order to
fully understand the potential of this model in the context
of PD. For this purpose, we performed herein a detailed
motor and non-motor behavioral characterization of the
unilateral MFB-lesioned PD model. In addition, to further
explore the relevance of combined therapeutic approaches
for PD, in which both motor and non-motor symptoms
are considered, we tested the ability of levodopa (LD), the
selective serotonin reuptake inhibitor (SSRI) paroxetine
(PRX) and the norepinephrine/dopamine reuptake inhibi-
tor bupropion (BUP), to revert some of the deficits
displayed in cases of severe PD-like lesions.
We show that 6-OHDA MFB injections caused a
variable level of dopaminergic degeneration in both
mesostriatal and mesocorticolimbic pathways, and signifi-
cantly contributed for the development of motor and spe-
cific non-motor impairments. Furthermore, we showed
that the pharmacological manipulation of the dopamin-
ergic (and noradrenergic) system is able to revert some of
the motivational/hedonic deficits found in cases of severe
MFB lesions.
Results
Phenotypic and histological characterization of
6-OHDA lesions
The apomorphine-induced turning test was performed
at the end of the behavioral assessment to gain insight
on the functional integrity of the dopaminergic system.
This test revealed the identification of two cohorts within
the 6-OHDA-lesioned group, one with marked turning
behavior (complete lesion), the other without intense
turning behavior (incomplete lesion) (Figure 1A). Statis-
tical analysis revealed differences in apomorphine-induced
turning behavior (H2 = 44.37; p < 0.001), with post-hoc
analysis revealing a significantly higher number ofrotations of the complete lesion group when compared to
both incomplete lesion and sham groups (p < 0.05).
This analysis was further complemented by an assess-
ment of tyrosine hydroxylase (TH)-immunohistochemistry
(Figure 1B). The quantification of lesion extent performed
through TH+ cells counts showed a marked degeneration
in area A9 (F2,11 = 442.6, p < 0.0001) (Figure 1C). Further
post-hoc analyses showed different degenerative profiles
between sham animals and both 6-OHDA injected ani-
mals and between incomplete and complete lesion groups
(p < 0.05), with incomplete lesion animals displaying ~70%
degeneration in the injected side, compared to spared
hemisphere and with complete lesion animals showing
~97% of TH+ cell loss (Figure 1C). In the case of area
A10, a significant effect of 6-OHDA lesions was also found
(F2,12 = 25.06, p < 0.0001) (Figure 1D). Both 6-OHDA
injected animals displayed significant loss of TH+ cells
when compared to controls (p < 0.05), with degeneration
ranging from ~40% in animals with incomplete lesion to
~60% in the complete lesion group (Figure 1D).
Motor performance after 6-OHDA lesions
Motor coordination, assessed in the rotarod (Figure 2A),
was significantly impaired after lesions with 6-OHDA
(F2,52 = 18.14, p < 0.0001). When compared to sham ani-
mals, both 6-OHDA-lesioned groups displayed clear motor
coordination deficits, being, as expected, these changes
greater in animals with complete lesions (p < 0.05).
Assessment of motor activity on the open field
(Figure 2B) revealed an effect of 6-OHDA lesions on
total distance travelled (F2,50 = 31.57, p < 0.0001), with
both 6-OHDA-lesioned groups displaying a significantly
lower motor activity than sham animals (p < 0.05); com-
parisons amongst the lesioned groups showed that the
one with complete lesion was the most affected
(p < 0.05). The effect of 6-OHDA lesions on movement
initiation was also significant (F2,50 = 30.59, p < 0.0001)
(Figure 2C). Comparisons between lesioned groups
showed no differences; however animals in both these
groups were clearly affected when compared to sham
animals (p < 0.05).
Effect of 6-OHDA lesions on anxiety and mood
The elevated plus maze (EPM) paradigm was used to as-
sess anxious-like behavior as a consequence of 6-OHDA
lesions Figure 3A. Figure 3B concerns data of acoustic
startle. No significant differences were found between
the groups regarding the ratio between time spent on
the open arms and time spent on the closed arms (H2 =
1.883, p = 0.39) (Figure 3A).
To overcome the influence of the motor component in
the interpretation of EPM data, we used the acoustic
startle response test as an additional measure of anxious-
like behavior (Figure 3B). Again, there was no significant
Figure 1 Characterization and quantification of 6-OHDA induced lesions. A) Apomorphine-induced turning behavior revealed two classes of
6-OHDA lesioned animals, those with reduced turning behavior (incomplete lesion) and those with intense turning behavior (complete lesion).
Sham animals showed no turning behavior. B) Representative photomicrographs of brain slices stained for TH. Compared to sham group, both
incomplete and complete lesion groups display marked reduction of TH staining in areas A9 and A10 of the lesioned hemisphere (*). Scale
bar = 1 mm. C) Quantification of lesion extent in area A9 shows a ~70% reduction of TH staining in the incomplete lesion group and a ~97%
reduction in the complete lesion group. D) Quantification of lesion extent in area A10 shows a ~40% reduction of TH staining in the incomplete
lesion group and a ~60% reduction in the complete lesion group. Sham n = 19; incomplete lesion n = 13; complete lesion n = 28. For histological
analysis sham n = 5; incomplete lesion n = 4; complete lesion n = 5. Data presented as mean ± SEM. ** p < 0.01, *** p < 0.001.
Carvalho et al. Molecular Neurodegeneration 2013, 8:14 Page 3 of 11
http://www.molecularneurodegeneration.com/content/8/1/14effect of 6-OHDA lesions in the startle response of the an-
imals to auditory stimuli with increased intensity (F2,245 =
2.197, p = 0.12). Nonetheless, there was a significant effect
of stimuli amplitude (F5,245 = 61.87, p < 0.0001) and of the
amplitude × lesion interaction (F10,245 = 2.093, p = 0.025).
Bonferroni post-hoc analysis showed a significantly lower
startle response for both 6-OHDA lesioned groups at
120 dB stimuli, when compared to the sham group
(p < 0.05).
Anhedonic behaviour, a key feature of depressive-like
behaviour, was tested with the sucrose preference test
(Figure 3C); importantly, this test is not significantly
dependent on locomotor performance as the forced swim-
ming test, the most commonly used test to assess
depressive-like behavior. The preference for a sweet solu-
tion was shown to be significantly affected by 6-OHDA le-
sions (H2 = 11.11, p = 0.004), with both incomplete and
complete lesion groups showing a robust decrease of pref-
erence when compared to sham animals (p < 0.05). These
results suggest a depressive-like behavior after 6-OHDA
lesions.Effects of 6-OHDA lesions in cognitive performance
The cognitive function of 6-OHDA-lesioned animals
was assessed by working and spatial reference memory
performance in the Morris water maze test (MWM)
(Figure 4). Analysis of path length during working mem-
ory task (Figure 4A), showed a significant effect of re-
peated sessions (F3,138 = 25.25, p < 0.0001), but no effect
of lesion (F2,128 = 1.146, p = 0.3269) or interaction be-
tween the variables (F6,138 = 1.846, p = 0.0946). In the
spatial reference memory task (Figure 4B) path length
analysis showed no effect of lesion (F2,135 = 1.062, p =
0.3541). Nonetheless, there was a significant effect of re-
peated sessions (F3,135 = 19.25, p < 0.0001) and the inter-
action of the variables (F6,135 = 2.472, p = 0.0267). In
other words, both reference and working memory per-
formance were not affected by 6-OHDA lesions.
Improving effects of levodopa and bupropion therapy in
non-motor symptoms
To test whether the non-motor deficits displayed by ani-
mals with 6-OHDA lesions could be ameliorated, we
Figure 2 Effect of unilateral dopaminergic degeneration on motor and exploratory behavior. A) Unilateral 6-OHDA lesion caused a
significant impairment in motor coordination on the rotarod test for both incomplete and complete lesion groups. B) On the open field arena
both 6-OHDA groups display a reduction in total distance travelled. C) Overall reduction in movement initiation in the open field caused by
6-OHDA lesion. Data presented as mean ± SEM. * p < 0.05, *** p < 0.001. For rotarod sham n = 18, incomplete lesion n = 13, complete lesion
n = 24. For open field sham n = 18, incomplete lesion n = 13, complete lesion n = 25.
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of antidepressants, PRX (6 mg/kg, i.p.) or BUP (10 mg/kg,
i.p.) to complete lesioned animals. Exploratory behavior
was assessed in the open field (Figure 5A); total distance
travelled was significantly improved with treatment (F3,56 =
7.123, p = 0.0004). Post-hoc tests showed the efficiency of
BUP in rescuing the deficits caused by complete 6-OHDA
-induced lesions compared to animals treated with vehicle
(p < 0.05), while in the case of LD its effect was only partial.
PRX showed no improving action. The effect of treatment
was also clear in movement initiation (H3 = 11.26, p =
0.0104) (Figure 5B), with BUP showing a significant im-
proving action (p < 0.05) when compared to vehicle-treated
animals, and LD only a modest effect. Again PRX had no
positive effect.
In the case of anhedonic behavior (Figure 5C) there was a
positive effect of treatment (H3 = 7.827, p = 0.049); post-hoc
comparisons revealed that LD significantly rescued
the decreased sucrose preference caused by 6-OHDA
lesions (p < 0.05). Additionally, BUP treatment was found
to have a partial (but not significant) effect in ameliorating
anhedonic symptoms, while PRX showed no effect.
Discussion
Our lesion protocol was successful in generating a rat
model with lesions in both mesostriatal and mesocor-
ticolimbic dopaminergic pathways. Interestingly, as shownby apomorphine-induced turning behavior, there were
two distinct cohorts within the 6-OHDA-injected group,
displaying different lesion extents. Animals displaying in-
tense turning behavior, showed a nearly complete unilat-
eral loss of TH+ neurons in the injected hemisphere, with
losses reaching ~97% and ~60% in A9 and A10 regions,
respectively. In turn, animals with moderate turning be-
havior displayed incomplete dopaminergic degeneration
with a TH+ neuronal loss around 70% in area A9 and 40%
in area A10. Remarkably, histological data revealed that
regardless of lesion extent, neurons in A9 were consist-
ently more affected than neurons in A10 in response to
6-OHDA, a result in accordance with reports supporting
the higher sensitivity of neurons in A9 to dopaminergic
insults [3,24,25].
Regarding motor function, we observed significant im-
pairments in motor coordination in both lesioned groups,
which were more severe in animals with more extensive
lesions, in agreement with previous reports showing im-
paired coordination and skilled motor function in animals
with DA lesion [21,26]. Besides deficits in motor coordin-
ation, lesioned animals also showed decreases in loco-
motor activity in the open field. As discussed elsewhere,
locomotor activity in the open field depends on motor
skills but also on the motivation to explore a novel arena
[27]. While it is true that the rotarod data supports the
idea that the reduced locomotion is, at least in part,
Figure 3 Impact of 6-OHDA lesions on anxious and depressive-like behavior. A) Related to sham animals incomplete and complete lesion
groups show no signs for increased anxiety, as seen by open arms/closed arms time ratio on the elevated-plus maze (EPM). B) Assessment of
acoustic startle response shows no signs of anxious-like behavior in both lesioned groups V-Avg = average startle response (arbitrary units).
dB = decibels. C) Compared to sham animals, 6-OHDA lesions caused anhedonic behavior in the sucrose preference test in both incomplete and
complete lesion groups Data presented as mean ± SEM. * p < 0.05, ** p < 0.01, *** p < 0.001, related to incomplete lesion, † p < 0.05, related to
complete lesion. For EPM and acoustic startle sham n = 17; incomplete lesion n = 12; complete lesion n = 24. For sucrose preference test sham
n = 17; incomplete lesion n = 12; complete lesion n = 28.
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mesostriatal degeneration, it is also plausible that the
lesion of the mesocorticolimbic network may contribute
to a decreased drive to explore. Indeed, several preclinical
and clinical studies support the role of this network, and
associated frontostriatal projection areas, in motivational
aspects of behavior [28-30]. Interestingly, this test also
showed a lower number of ambulatory episodes in animals
with 6-OHDA-induced DA lesions. This phenomenonFigure 4 Cognitive repercussions of unilateral dopaminergic degener
differences between both incomplete and complete lesion groups and the
were no differences in path length between sham animals and either inco
n = 13; complete lesion n = 19. Data presented as mean ± SEM.may evoke the bradykinesia that characterizes PD, and is
associated with mesostriatal dysfunction [6,31].
To further understand the behavioral implications of
MFB dopaminergic lesions we assessed the presence of
anxious-like behavior in this model. Whether anxiety is
directly linked to DA degeneration or is a consequence
of PD medication is still a matter of dispute [8,14]; how-
ever, anxiety symptoms are very common in PD patients
and some authors state that anxiety in PD can beation. A) Path length analysis in the working memory task shows no
sham group. B) On the spatial reference memory task of MWM there
mplete and complete lesion groups. Sham n = 18; incomplete lesion
Figure 5 Effect of dopaminergic and antidepressant therapy of animals with complete DA unilateral lesions. A) On the open field arena
bupropion (BUP) treatment significantly rescued spontaneous locomotion, whereas levodopa (LD) had a partial effect. Paroxetine (PRX) had no
effect, related to vehicle-treated animals. B) BUP treatment improved motor initiation in the open field, while the effect of LD was partial. PRX
had no effect when compared to vehicle treatment. C) Anhedonic behavior was significantly improved with LD treatment and partially by BUP,
compared to vehicle-treated animals, while PRX showed no effect. Data presented as mean ± SEM. * p < 0.05, ** p < 0.01. Results from an additional set
of animals distributed as following according to treatment: Vehicle n = 37; LD n = 10; PRX = Paroxetine n = 10; BUP = Bupropion n = 9.
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symptoms [14,32]. Curiously, experimental data in animal
models of PD is also inconclusive. While a recent study
showed no effect of bilateral MFB lesions on anxiety [33],
previous studies had reported a significant anxiolytic effect
of bilateral 6-OHDA lesions in the striatum [34], or even
higher levels of anxiety in animals with either unilateral
MFB lesions [35,36] or bilateral striatal lesions [37]. Our
results on the EPM show no signs for the presence of
anxiety-like behavior in animals with both incomplete and
complete lesions. However, these animals also displayed
reduced mobility in the maze (data not shown), which can
confound the interpretation of the results. The assessment
of acoustic startle responses was thus important to over-
come the influence of the motor component on the EPM,
as in this test the animals are not required to move. In line
with the results on the EPM, the assessment of startle re-
sponses does not support the presence of anxious-like be-
havior, since both groups of animals with 6-OHDA lesions
display even a decreased startle response to acoustic stim-
uli, when compared to sham-lesioned animals. On the
light of these, but also previous findings, anxiety does not
seem to be a common feature of this PD model.
On the spectrum of mood-related changes associated
with human idiopathic PD, depression is also known to
have a high prevalence, and to significantly affect the
quality of life of patients [15,38]. It is widely accepted
that dopamine is implicated in mood homeostasis [39]
and, as for anxiety, depression can occur in PD patients
even before the appearance of the first motor symptoms
[40]. In the present study, we found that animals with ei-
ther incomplete or complete unilateral DA denervation
presented marked decrease in sucrose preference, indica-
tive of depressive-like behavior. These results are in linewith several studies in rodent models of PD [35,41-45];
interestingly, and fitting with the hypothesis that in human
PD depression can emerge prior to motor disabilities, signs
of depressive-like behavior were even described in models
of pre-symptomatic stages of PD [34,37,46]. Bearing in
mind the critical role of the mesocorticolimbic pathway in
reward and hedonia, our results can be explained by the
extent of dopaminergic denervation caused by 6-OHDA
injections in this pathway. However, in contrast to the
observed association between the extent of mesostriatal
lesions and motor performance, our results indicate that
the degree of mesocorticolimbic degeneration is not de-
terminant for the magnitude of mood affection, namely
anhedonic behavior. Importantly, the degeneration of
mesostriatal neurons may also play a role in the devel-
opment of these mood alterations as it was already
proved that lesions in SNc could cause similar results
[42,43]. However, the contribution of the mesostriatal
pathway seems to be highly dependent on lesion site,
and its effect upon projection areas, as lesions limited to
the striatum failed to cause increased behavioral despair
and anhedonia [34].
Several cognitive impairments, namely visuo-spatial,
long-term and working memory deficits, set-shifting im-
pairments, and ultimately dementia, are frequently asso-
ciated with PD, as a result of mesocortical dopaminergic
degeneration [10,47-50]. Accordingly, studies performed
in animal models of PD showed how DA lesions were
found to have a negative effect on cognitive performance
[51-56]. However, in the present work, unilateral MFB
lesions had no effect in any of the lesioned groups regard-
ing both working and spatial reference memory function.
We can hypothesize that our unilateral MFB lesions were
not extensive enough to cause significant deficits on the
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affecting both hemispheres will effectively reproduce cog-
nitive impairments reminiscent of human PD [52-56].
After the behavioral characterization of our model, we
decided to test whether the non-motor deficits observed
in animals with complete lesions could be pharmaco-
logically reverted; for that purpose we administered LD,
to assess the effect of DA restoration, and two antidepres-
sants, PRX and BUP (inhibitors of reuptake of serotonin
and dopamine/norepinephrine, respectively). Compared
to vehicle-treated animals, the administration of both LD
and BUP improved exploratory behavior on the open field,
particularly in the case of BUP. Improvements in this task
are likely linked to some degree of motor rescue, com-
bined with mood elevation leading to increased motiv-
ation to explore. In fact, we also noted a positive effect of
both LD and BUP in hedonic behavior, given that both
treatments increased the preference for sucrose, particu-
larly LD. Even though the effect of both LD and BUP was
not consistent in all behavioral measures and in some
cases their action only partially rescued behavioral deficits,
these results suggest that the non-motor changes found in
animals with complete 6-OHDA-induced lesions are
closely linked to changes in dopaminergic function. Clin-
ical studies have shown how non-motor symptoms of PD
are responsive to different dopaminergic treatments [57],
and how LD is able to promote improvements in affective
and apathetic symptomatology [12,58-60]. In animal
models of PD, LD also proved to be beneficial for both
mood and cognition [43,61]. In the case of BUP several re-
ports have demonstrated how this drug has important
stimulant properties, inducing hyperactivity in rodents on
the open field [62-66]. This may help explaining the im-
provements we observed regarding exploratory activity.
However, it should not be excluded the hypothesis that a
mood improving action of BUP might also increase ex-
ploratory drive. In support of this hypothesis, our BUP
treatment showed some potential to rescue anhedonic
symptoms, and in fact BUP was already shown to be able
to ameliorate depressive-like behavior [64,67]. Moreover,
there is evidence proving the beneficial action of BUP in
the treatment of depressive symptoms of PD [68,69].
Despite the relevance of DA network degeneration for
the appearance of motor and non-motor symptoms in
PD, the contribution of other neurotransmitters systems
has also been the focus of several studies. For example,
changes on the serotonergic system have also been de-
scribed in the context of PD, and linked to the emer-
gence of mood changes [9,70]. In animal models of PD
the implication of changes in the serotonergic system
and their relation with DA is not completely clear; in
fact different studies found that DA lesions can either
upregulate or downregulate serotonergic signaling [70].
Regardless of that, PRX, a common SSRI antidepressant,was recently shown to have positive action on mood in
patients with PD [71], contradicting earlier reports [72].
Interestingly, our data suggests that in this particular
model, behavioral deficits are unlikely related with sero-
tonergic transmission, given that PRX administration
was not successful in ameliorating any behavioral deficit.
Changes in norepinephrine (NE) can further account for
affective changes seen in PD [13]; and in line with this a
combined serotonin/norepinephrine reuptake inhibitor
was already shown to have mood improving actions in
patients unresponsive to SSRI therapy [73]. Importantly,
lesion protocols using 6-OHDA are known to affect NE
transmission [37,74], which in the present study could
play a role on the emergence of the mood changes
reported. Given the additional role of BUP in inhibiting
NE reuptake, we can hypothesize that its mood improv-
ing effect can be partially explained by the modulation
of NE transmission, though further studies are needed.
Conclusions
In summary, we showed that the unilaterally MFB
6-OHDA-lesioned model of PD presents a significant
disruption in both mesostriatal and mesocorticolimbic
dopaminergic pathways, with significant consequences on
motor and some specific non-motor behaviors. Moreover,
our results reveal that pharmacological manipulations of
dopaminergic and noradrenergic signaling are efficient in
rescuing many of these behavioral deficits, whereas seroto-
nergic pathway does not seem so relevant in this context.
This model can thus be used as a reliable tool to assess
the effect of new treatments on multiple aspects of PD
dysfunction and to test the efficiency of combined
therapeutical approaches for PD, tackling both motor and
non-motor features of the disease.
Methods
Animals and 6-OHDA Lesions
Eleven week old Wistar-Han male rats (Charles River,
Barcelona) were housed, two per cage, under standard
laboratory conditions: 12 hour light–dark cycle, 22°C
room temperature, 55% relative humidity, food and water
available ad libitum. All manipulations were done in
accordance with the local regulations (European Union
Directive 2010/63/EU) and NIH guidelines on animal care
and experimentation.
Under ketamine-medetomidine (75 mg/kg: 0,5 mg/kg,
i.p.) anesthesia the animals were placed on a stereotaxic
frame with non-traumatic ear bars (Stoelting, USA), and
unilaterally injected using an 30-gauge needle Hamilton
syringe (Hamilton Company, Switzerland), with either ve-
hicle (sham group, n = 19) or 6-OHDA hydrochloride
(Sigma, USA) (6-OHDA group, n = 41) directly into the
medial forebrain bundle (coordinates related to Bregma,
AP = −4,4 mm; ML = −1,0 mm; DV = −7,8 mm; according
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animals received 4 μl of 0,2 mg/ml ascorbic acid in 0,9%
NaCl and 6-OHDA animals were injected with 4 μl
6-OHDA hydrochloride (3 μg/μl) with 0,2 mg/ml ascorbic
acid in 0.9% NaCl. After injection the syringe was left in
place for 4 minutes to allow diffusion. Behavioral assess-
ment began three weeks after surgery.
Behavioral assessment
Rotarod
Motor performance was evaluated on a Rotarod equip-
ment (3376-4R; TSE Systems, USA), under an accelerating
protocol previously described [21]. The first 3 days of test-
ing served as training. The animals underwent a four trial
test under an accelerating protocol going from 4 rpm to
40 rpm in 5 minutes, being allowed to rest for at least
20 minutes between trials. On the fourth day, using the
same protocol, the latency to fall was recorded.
Open field
To assess exploratory activity, the animals were tested in
the Open Field arena (ENV-515, Med Associates inc.
USA) for 5 minutes, as previously described [76]. Total
distance travelled and number of ambulatory episodes
were recorded using a tracking software (SOF-811, Med
Associates).
Elevated plus maze
To assess anxious-like behavior the animals were tested
on an elevated plus maze (EPM) (ENV-560; Med Associ-
ates) as previously described [77]. Animals were placed
in the central junction facing an open arm, and allowed
to explore for 5 minutes. The test was recorded and the
ratio between time in open arms and time in closed
arms was measured.
Acoustic startle
Startle reflexes were measured in two identical startle re-
sponse systems (SR-LAB, San Diego Instruments, USA)
as previously described [77]. The animals were placed
inside a ventilated, sound-attenuated chamber on a non-
restrictive Plexiglas cylinder (i.d. 8.8 cm, length 22.2 cm).
Cylinder movements were detected and measured by a
piezoelectric element attached to the cylinder. Startle
stimuli, presented through a high frequency speaker were
sampled each millisecond (ms) during a period of 150 ms
beginning at the onset of the startle stimulus. During this
period average startle responses were recorded. Animals
were habituated to the apparatus for 5 min, 24 hours be-
fore the test was performed. On the day of the test, after a
5 min habituation period each animal was presented five
baseline startle stimuli (50-ms pulse of white noise at
120 dB) at an interstimulus interval of 30 s, followed by
the random presentation of 52 startle stimuli, each with50 ms in duration, and intensity between 70 to 120 dB, in
10-dB increments.
Sucrose preference test
To assess the presence of anhedonic behavior the ani-
mals were exposed to the sucrose preference test (SPT),
adapted from Bessa et al. [78]. After 20 h of food and
water deprivation the animals were placed in individual
cages and presented with pre-weighted bottles, one
containing tap water, the other one filled with 3% su-
crose. Sucrose and water intake were measured as the
difference between the initial and the final weight of
the bottle. Sucrose preference was calculated according to
the formula: sucrose preference = [sucrose intake/(sucrose
intake + water intake)] × 100.
Morris water maze
To test cognitive function the animals were submitted to
the Morris water maze test (MWM) as previously de-
scribed [79]. Briefly, a black pool was divided into four
quadrants, each associated with an extrinsic visual cue.
The pool was filled with water (25°C), and a platform, in-
visible to the animals was submerged 1 cm below surface.
The working memory task was conducted during four
days, with the animals performing four trials, 2 minutes
each. Each trial had a different starting position. The
trial ended either when the animal reached the platform
or after 2 minutes. In the later case the animals were
guided to the platform. The animals were allowed to rest
in the platform for 20 seconds between each trial. In
each of the four days the platform was hidden in a dif-
ferent position.
The spatial reference memory task was performed dur-
ing four days with the first of them being the last of the
working memory task. Experimental conditions were the
same but with platform position kept constant for all
the days. In both the working memory and spatial refer-
ence memory tasks the path length to reach the platform
was recorded (View Track v.2.6., View Point Life Sciences
inc., France). Animals showing persistent thigmotaxis or
spending the entire test floating were excluded from the
analysis.
Apomorphine turning behavior
To test apomorphine-induced turning behavior the ani-
mals received in the neck a subcutaneous injection of
0,05 mg/kg apomorphine hydrochloride (Sigma) dissolved
in 1% ascorbic acid 0,9% NaCl, and placed on metal testing
bowls (MED-RSS, Med Associates) for 45 minutes. The
number of contralateral rotations was digitally recorded,
and 6-OHDA-lesioned animals presenting more than 100
rotations in 45 minutes were considered to have a nearly
complete lesion (n = 28), whereas the ones presenting less
than 100 rotations were classified as having an incomplete
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behavior.
Histology
TH immunohistochemistry and lesion quantification
Animals were sacrificed with sodium pentobarbital, and
transcardially perfused with a 4% paraformaldehyde in
0,1 M PBS. Mesencephalon coronal sections, 30 μm
thick, were obtained with a vibratome (VT1000S, Leica,
Germany). Four series of consecutive slices were ob-
tained and one was processed for free-floating TH-
immunohistochemistry. Briefly, slices were immersed
for 20 minutes in 1 M PBS with 3% H2O2, followed by
blocking for 2 hours with 5% fetal calf serum in 1 M PBS.
Slices were then incubated over-night at 4°C with rabbit
anti-mouse TH primary antibody (Millipore, USA, 1:2000
in 2% fetal calf serum in 1 M PBS), followed by incubation
for 30 minutes with a biotinylated secondary anti-rabbit
antibody (LabVision, USA), and 30 minutes incubation
with an Avidine/Biotine complex (LabVision). Antigen
visualization was performed with 3,3í-diaminobenzidine
tetrahydrochloride (DAB, Sigma) (25 mg DAB in 50 ml
Tris–HCl 0,05 M, pH 7,6 with 12,5 μl H2O2) and stopped
at the desired time. The slices were mounted on superfrost
slides and thionin counter-coloration was performed.
To assure a representative sampling between animals,
six identical TH-labeled slices spanning the entire mesen-
cephalon and including both A9 and A10 brain regions
were selected in 5 animals per group. Using a bright-field
microscope (BX51, Olympus, USA) equipped with a
digital camera (PixeLINK PL-A622, CANIMPEX Enter-
prises Ldt., Canada), and with the help of Visiomorph™
software (V2.12.3.0, Visiopharm, Denmark) the boundar-
ies of A9 and A10 areas were drawn. Delineation of re-
gions of interest was performed through identification of
anatomic reference points and with the help of rat brain
atlas [75]. The A9 area included all the portions of SNc,
whereas the A10 group included the ventral tegmental
area, parabrachial nucleus, paranigral nucleus, rostral and
caudal linear nuclei and interfascicular nucleus, as previ-
ously described [25]. Counting of total TH+ neurons in
the areas drawn was performed on both hemispheres and
the data presented as % of remaining TH+ neurons in the
injected side, compared to the control side.
Treatments
Treatments started two weeks before the behavioral as-
sessment and continued until its end. Animals were
treated daily with therapeutical doses of either paroxe-
tine (PRX, n = 10) (6 mg/kg) or bupropion (BUP, n = 8)
(10 mg/kg) dissolved in water. For levodopa (LD, n = 10)
treatment, Sinemet pills (25 mg carbidopa/100 mg levo-
dopa, Merck Sharp & Dohme, S.p.A, Italy) were smashed
and suspended in tap water (5 mg/kg carbidopa + 25 mg/kglevodopa) and given orally 3 h before behavioral assess-
ment. Behavior was then assessed between 3 and 4 h post-
treatment, a therapeutical window with lower dyskinetic
profile. An additional group (n = 37) received both i.p.
injections and oral administration of water (Vehicle).
Statistical analysis
All data was analyzed using the program GraphPad
Prism 5 (GraphPad Software Inc., La Jolla, CA, USA).
One-way ANOVA followed by Tuckey’s post-hoc test
was used for analysis of data with Gaussian distribution.
Non-gaussian data was analyzed with non-parametric
analysis of variance (Kruskal-Wallis) followed by Dunn’s
post-hoc test. Morris Water Maze and Acoustic Startle
data were analyzed with repeated measures ANOVA,
with time and acoustic intensity as within-group vari-
able, respectively; followed by Bonferroni post-hoc test.
All data shown has Mean ± S.E.M. Significance value set
at p < 0.05.
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